Celltrion Healthcare Reports Q3 Operating Profit of 127.7 Billion KRW... Record High

[Asia Economy Reporter Dongwoo Lee] Celltrion Healthcare announced on the 16th that its consolidated operating profit for the third quarter of this year reached 127.7 billion KRW, marking a 500% increase compared to the same period last year and setting a record high for a single quarter.

During the same period, sales increased by 64% to 463.4 billion KRW, and net profit rose by 753% to 86.1 billion KRW.

The cumulative sales for the third quarter of this year reached 1.2406 trillion KRW, surpassing last year's annual sales of 1.1009 trillion KRW. The operating profit margin also showed a high profitability at 28%.

Celltrion Healthcare explained that the stable prescription performance of major products such as 'Remsima' (generic name Infliximab), 'Truxima' (generic name Rituximab), and 'Herzuma' (Trastuzumab) in Europe, along with rapid growth in the United States, were the main reasons for the improved performance.

In particular, Truxima achieved a market share of 20.4% in September this year, just 11 months after its launch in the U.S., according to Symphony Health, a medical information provider.

This content was produced with the assistance of AI translation services.